FDA Regulatory Framework for Digital Health and Wellness Technologies

FDA Regulatory Framework for Digital Health and Wellness Technologies

The U.S. Food and Drug Administration applies a risk-based framework to digital health and wellness technologies that centers on a product’s intended use. In its guidance documents, the agency states that apps limited to general wellness claims are not classified as medical devices and are not subject to FDA regulation [1][3]. The framework distinguishes low-risk wellness tools from software that performs diagnosis, treatment, or patient-specific analysis [2][4].

This approach, formalized through the Digital Health Center of Excellence launched in 2020, clarifies regulatory pathways while the agency exercises enforcement discretion for many low-risk products [1]. The policy has shaped how digital wellness software reaches communities.

What this means

The distinctions in FDA guidance mean that many digital tools focused on physical activity, stress management, or healthy eating can be developed and distributed without premarket review. Products that avoid specific disease claims remain outside device regulation, while those meeting the statutory definition of a medical device face oversight scaled to risk level. This structure has concentrated FDA attention on higher-risk software functions rather than broad consumer wellness applications.

How Does the FDA Classify and Regulate Digital Wellness Apps According to Current Guidance?

The FDA does not classify or regulate most digital wellness apps as medical devices when their intended use is limited to general wellness without specific claims to diagnose, treat, mitigate, cure, or prevent a disease or medical condition [1][3]. Regulation applies only if the software meets the statutory definition of a device under the Federal Food, Drug, and Cosmetic Act. The agency applies a risk-based approach and often exercises enforcement discretion for low-risk wellness products per its published guidance [2][4].

What specific criteria does the FDA use to decide whether a mobile app qualifies as a regulated medical device?

Intended use determines device status. FDA guidance states that regulatory oversight applies only to apps that transform a mobile platform into a regulated medical device or that perform patient-specific analysis for diagnosis or treatment [2]. Apps making only general wellness claims fall outside this definition and are not regulated as devices [1][3].

Which official FDA guidance documents address general wellness, Software as a Medical Device (SaMD), and mobile medical applications?

Three primary FDA documents establish the current framework. The “General Wellness: Policy for Low Risk Devices” defines two categories of products the agency does not intend to examine: those maintaining or encouraging a general state of health, and those helping reduce risk or support living well with chronic disease without specific disease claims [3]. The September 2019 “Policy for Device Software Functions and Mobile Medical Applications” details when software functions trigger oversight [2]. The SaMD resource outlines the risk-based classification framework used for digital health software [4].

What are concrete examples of wellness apps that fall outside FDA oversight versus those that require review?

FDA policy places apps that track general physical activity or offer meditation for everyday stress management in the unregulated general wellness category when no disease-specific claims are made [3]. In contrast, software that conducts patient-specific analysis to diagnose a condition or guide treatment of a disease meets the definition of a regulated device and is subject to FDA review [2].

How does the Digital Health Center of Excellence influence oversight of digital wellness tools?

The FDA launched the Digital Health Center of Excellence in 2020 to centralize expertise and policy development for digital health technologies including wellness applications [1]. The center clarifies regulatory pathways, supports consistent application of risk-based approaches, and serves as the primary resource for developers seeking guidance on SaMD and general wellness policies [4].

Limitations

Guidance is interpretive and subject to update; specific app functionality may require case-by-case FDA consultation. This piece covers only U.S. FDA policy and excludes international frameworks (EMA, WHO) or state-level rules. No individual app review or legal advice is provided.